文献速递乳腺MR

术前乳腺MRI对穿刺活检为浸润性导管癌伴或不伴导管原位癌成分患者手术结局的影响:MIPA研究

Preoperative breast MRI for invasive ductal carcinoma with or without a DCIS component at needle biopsy: influence on surgical outcomes in the MIPA study.
PubMed 文献 · Eur Radiol · 2025-04-24

基于多中心前瞻性MIPA数据库,分析术前乳腺MRI对穿刺活检为纯浸润性导管癌或浸润性导管癌伴导管原位癌患者手术结局的影响。匹配后显示,在浸润性导管癌伴导管原位癌组,MRI组全乳切除率更高且未降低再手术率;在纯浸润性导管癌组,MRI组再手术率更低且未增加全乳切除率。

要点

  • 穿刺活检为浸润性导管癌伴导管原位癌时,术前MRI与更高的全乳切除率相关,未降低再手术率。
  • 穿刺活检为纯浸润性导管癌时,术前MRI与更低的再手术率相关,且未增加全乳切除率。
  • 穿刺活检为浸润性导管癌时,术前是否行MRI应结合是否伴导管原位癌成分来考虑。

核心结论

  • 在浸润性导管癌伴导管原位癌患者中,术前MRI未减少再手术并增加了全乳切除;相反,在纯浸润性导管癌患者中,术前MRI减少了再手术且未增加全乳切除。

研究设计与样本

  • 多中心国际前瞻性分析(MIPA)数据库研究,纳入18-80岁穿刺活检诊断为纯浸润性导管癌或浸润性导管癌伴导管原位癌并接受 upfront 手术的患者,按8个混杂协变量进行1:1匹配比较术前MRI组与未行MRI组的手术结局。

诊断标准与关键数值

  • 浸润性导管癌伴导管原位癌匹配后每组255例:MRI组 vs 未行MRI组一线全乳切除率13.3% vs 6.3%(OR 2.30,p=0.011),总全乳切除率14.5% vs 7.5%(OR 2.11,p=0.016),再手术率9.4% vs 10.6%(OR 0.88,p=0.768)。
  • 纯浸润性导管癌匹配后每组819例:MRI组 vs 未行MRI组一线全乳切除率12.9% vs 12.1%(OR 1.08,p=0.654),再手术率2.6% vs 7.9%(避免再手术OR 3.28,p<0.001),总全乳切除率13.6% vs 13.7%(OR 0.99,p=1.000)。

临床应用与阅片要点

  • 穿刺活检为浸润性导管癌时,决定是否行术前乳腺MRI应考虑是否伴导管原位癌成分,因为MRI对手术结局的获益仅在纯浸润性导管癌患者中观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To analyse the impact of preoperative breast MRI on surgical outcomes of patients diagnosed with pure invasive ductal carcinoma (IDC) or IDC with an associated in situ component (IDC + ductal carcinoma in situ [DCIS]) at needle biopsy.

METHODS: Patients aged 18-80 years referred for upfront surgery after a diagnosis of pure IDC or IDC + DCIS at needle biopsy were retrieved from the Multicenter International Prospective Analysis (MIPA) database. In each subgroup, patients who underwent preoperative MRI (MRI groups) were matched 1:1 to those who did not (noMRI groups) according to eight confounding covariates. Surgical outcomes were compared with non-parametric statistics after calculating odds ratios (ORs).

RESULTS: Among 1051 patients with IDC + DCIS, 510 were retained after matching (255 in each group): in comparison to the noMRI group, the MRI group had significantly higher rates of first-line mastectomy (13.3% vs 6.3%; OR 2.30, p = 0.011) and of overall mastectomy (14.5% vs 7.5%; OR 2.11, p = 0.016), without significantly lowering the reoperation rate (9.4% vs 10.6%, OR 0.88, p = 0.768). Among 2459 patients with pure IDC, 1638 were retained after matching (819 in each group): the first-line mastectomy rate was not significantly higher in the MRI group (12.9% vs 12.1% in the noMRI group; OR 1.08, p = 0.654). Instead, the reoperation rate was significantly lower (2.6% vs 7.9%; OR 3.28 for avoiding reoperation, p < 0.001) with no increase in overall mastectomies (13.6% vs 13.7%: OR 0.99, p = 1.000).

CONCLUSIONS: In patients with IDC + DCIS, preoperative MRI did not reduce reoperations and increased mastectomies. Conversely, in patients with pure IDC, preoperative MRI reduced reoperations without increasing mastectomies.

KEY POINTS: Question The impact of preoperative breast MRI on surgical outcomes of patients with IDC at needle biopsy is controversial and lacks large-scale investigations. Findings For pure IDC at needle biopsy, MRI reduced reoperations without increasing mastectomies; for IDC + DCIS, MRI did not reduce reoperations and increased mastectomies. Clinical relevance In patients with IDC at needle biopsy, the decision to perform preoperative breast MRI should take into account the presence of associated DCIS, as the benefits of MRI on surgical outcomes were observed only in patients with pure IDC.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Cozzi A, Di Leo G, Houssami N, et al. Preoperative breast MRI for invasive ductal carcinoma with or without a DCIS component at needle biopsy: influence on surgical outcomes in the MIPA study. Eur Radiol. 2025. PMID: 40272491. doi:10.1007/s00330-025-11572-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。